کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2151875 | 1090029 | 2009 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
CRPCAEDDHTPSABMDImmunohistochemistry - ایمونوهیستوشیمیIHC - ایمونوهیستوشیمیBone mineral density - تراکم معدنی استخوانtestosterone - تستوسترونintraperitoneal - داخل صفاقیDihydrotestosterone - دی هیدروتستوسترونProstate cancer - سرطان پروستاتCastration-resistant prostate cancer - سرطان پروستات مقاوم به کاستاریکاandrogen response element - عنصر پاسخ آندروژنARE - هستندprostate-specific antigen - پادگن مخصوص پروستاتCaP - کلاه لبه دارAndrogen Receptor - گیرنده آندروژنی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most patients eventually develop castration-resistant CaP (CRPC) for which highly effective therapies are limited. We explored the efficacy of a novel agent, HE3235, in inhibiting growth of CRPC in preclinical models. Castrated male mice were implanted subcutaneously with LuCaP35V CaP xenografts in the presence and absence of 5â²-androstenediol (AED) and treated with HE3235. To investigate the effect of HE3235 on CaP tumor in the bone, castrated mice were injected intratibially with C4-2B CaP cells and treated with HE3235. Serum prostate-specific antigen (PSA) levels, tumor volume, immunohistochemistry, gene expression, and levels of intratumoral androgens were analyzed. HE3235 significantly prolonged the tumor doubling time of LuCaP35V, decreased androgen receptor expression, and lowered levels of intratumoral testosterone by â¼89% and dihydrotestosterone by â¼63% in both the presence and the absence of AED. HE3235 inhibited tumor growth in the bone environment. Weights of tumored tibiae of HE3235-treated animals were lower than those of control (P = .031), and normalized PSA levels were also significantly decreased at the end of study by HE3235 treatment (P = .0076). HE3235 inhibits the growth of subcutaneous CRPC as well as CRPC in the bone environment. Our data show that HE3235 exhibits a wide range of effects, including alteration of androgen receptor signaling and reductions in levels of intratumoral androgens. Our results support ongoing clinical investigations into the effectiveness of HE3235 in the setting of CRPC and warrants further studies into the mechanisms behind the effects of HE3235.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Neoplasia - Volume 11, Issue 11, November 2009, Pages 1216-1225, IN22-IN23
Journal: Neoplasia - Volume 11, Issue 11, November 2009, Pages 1216-1225, IN22-IN23
نویسندگان
Theodore D. Koreckij, Richard J. Trauger, Robert Bruce Montgomery, Tiffany E.M. Pitts, Ilsa Coleman, Holly Nguyen, Chris L. Reading, Peter S. Nelson, Robert L. Vessella, Eva Corey,